Glucocorticoidsare used by an estimated 0.5% to 1.0% of adults for management of a range
of conditions, from allergies and inflammatory diseases to cancer. 1 Glucocorticoid use …

Objective Glucocorticoids constitute a considerable risk for developing osteoporosis in both
younger and older adults. However, currently available bone imaging modalities and …

Allogeneic hematopoietic cell transplantation (allo-HCT) is a potentially curative treatment
for patients with a hematologic disease. Although the clinical outcomes after allo-HCT have …

Objective The objective is to update recommendations for prevention and treatment of
glucocorticoid‐induced osteoporosis (GIOP) for patients with rheumatic or nonrheumatic …

Background: Glucocorticoids are of substantial therapeutic importance in the treatment of
inflammatory diseases, but are also associated with bone mineral density loss, osteoporosis …

Glucocorticoid-induced osteoporosis (GIO) is a significant side effect of prolonged
glucocorticoid (GC) treatment. Chronic GC treatment also leads to trabecular bone loss and …

The gut microbiota and barrier function play important roles in bone health. We previously
demonstrated that chronic glucocorticoid (GC)-induced bone loss in mice is associated with …

Glucocorticoid-induced osteoporosis (GIOP) is a frequently encountered and serious side
effect of glucocorticoid use. Bone loss leading to an increased risk for fracture occurs early in …

Objectives Chronic glucocorticoid use is complicated by osteoporosis and increases the risk
of fragility fractures. EULAR guidelines on SLE management recommend reducing chronic …

Purpose Fracture risk assessment is recommended at three months after glucocorticoid (GC)
therapy initiation. This study aimed to assess whether GC exposure in the initial 90 days of …